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that decreased Treg distribution in the BM correlated with 
increased Treg redistribution to tumor tissue, suggesting 
that TCR triggering induces a translocation of Treg from 
the BM into tumor tissue. Sphingosine-1-phosphate recep-
tor 1 (S1P1)—which is known to mediate exit of immune 
cells from lymphoid organs was selectively expressed by 
tumor antigen-specific BM Treg. S1P1 expression could 
be induced in Treg by BM-resident antigen-presenting 
cells (BMAPCs) in conjunction with TCR stimulation, but 
not by TCR stimulation or BMAPCs alone and triggered 
the migration of Treg but not conventional T cells (Tcon) 
to its ligand Sphingosine-1-phosphate (S1P). Interestingly, 
we detected marked S1P gradients between PB and BM in 
breast cancer patients but not in healthy individuals. Taken 
together, our data suggest a role for S1P1 in mediating the 
selective mobilization of tumor specific Treg from the BM 
of breast cancer patients and their translocation into tumor 
tissue.
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Abbreviations
ADCC  Antibody-dependent cell-mediated cytotoxicity
APC  Antigen-presenting cells
BM  Bone marrow
BMAPCs  BM-resident antigen-presenting cells
BMMCs  Bone-marrow mononuclear cells
CLIP  Class II-associated invariant chain peptide
FFPE  Formalin-fixed paraffin embedded
HD  Healthy donor
Mam  Mammaglobin
PB  Peripheral blood
PBMCs  Peripheral blood mononuclear cells
Abstract Regulatory T cells (Treg) hamper anti-tumor 
T-cell responses resulting in reduced survival and failure of 
cancer immunotherapy. Among lymphoid organs, the bone 
marrow (BM) is a major site of Treg residence and recir-
culation. However, the process governing the emigration 
of Treg from BM into the circulation remains elusive. We 
here show that breast cancer patients harbour reduced Treg 
frequencies in the BM as compared to healthy individu-
als or the blood. This was particularly the case for tumor 
antigen-specific Treg which were quantified by MHCII 
tumor peptide loaded tetramers. We further demonstrate 
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S1P  Sphingosine-1-phosphate
S1P1  Sphingosine-1-phosphate receptor 1
SEB  Staphylococcus aureus enterotoxin B
Tcon  Conventional CD4+ T cells
Tet  Tetramer
Treg  Regulatory T cell(s)
TSDR  Treg specific demethylated region
Introduction
Treg are a subset of CD4+ T cells that maintain self toler-
ance by exerting a plethora of immune suppressive activi-
ties on various immune cells—most prominently autore-
active T effector cells. Treg also play a detrimental role in 
anti-tumor T-cell responses in cancer patients. Infiltration 
of Treg into tumors is associated with enhanced tumor 
growth and poor prognosis [1–3] and their therapeutic 
depletion through antibody-dependent cell-mediated cyto-
toxicity (ADCC)-proficient antibodies against a Treg-asso-
ciated molecule CTLA-4 or low-dose cyclophosphamide 
treatment can improve anti-tumor T-cell responses and 
overall survival of patients [4, 5]. Conversely, in tumors 
promoted by chronic inflammation, Treg infiltration is 
beneficial as it dampens inflammation [6]. Together, data 
available until date clearly demonstrate the prognostic rele-
vance of tumor infiltrating Treg [7]. This is also the case in 
breast cancer. Many breast cancer patients not only develop 
tumor antigen-specific effector T-cell responses [8–12], but 
also tumor specific Treg [13]. Treg accumulation in breast 
tumors is associated with poor overall and relapse free sur-
vival and used as an independent prognostic factor in pre-
dicting patients at high risk of relapse [14].
T-cell entry into peripheral tissues requires their exit 
from lymphoid organs, where they reside until their mobi-
lization into the blood. Such an exit can be triggered by 
antigen-specific activation [15] or by changes in chemokine 
gradients and related signals [16]. The BM is an impor-
tant lymphoid organ for Treg accumulation and recircula-
tion and thus an important source of tumor infiltrating Treg 
[17]. However, the events triggering Treg exit from BM 
into PB remain largely elusive.
Here we addressed a potential role for S1P1 in regulat-
ing Treg exit from BM into PB in breast cancer patients. 
S1P1 mediates immune cell exit [18], particularly T cell 
exit from thymus and lymph nodes [19, 20]. Sawicka et al. 
provided evidence that treatment of mice with an S1P1 ago-
nist resulted in an accumulation of Treg in PB and spleen 
but not in lymph nodes, while the same treatment resulted 
in increased lymph node accumulation of naïve CD4+ T 
cells suggesting that S1P1 could be involved in differential 
sequestration of Treg [21]. Cell surface residence of S1P1 
is crucial to determine cell egress and is tightly regulated 
by S1P concentrations in the microenvironment thereby 
modulating trafficking patterns. It was reported that acti-
vation induces migration of lymph node Treg towards S1P 
[22] and that Treg tend to lose S1P1 more slowly from the 
surface upon activation in contrast to Tcon [23]. Hence, 
we here wondered whether in breast cancer patients S1P1 
might be involved in the emigration of Treg populations 
from the BM.
Using PB and BM samples from breast cancer patients, 
we studied the expression, induction, and functional rele-
vance of S1P1 and its ligand S1P in bulk and tumor anti-
gen-specific Treg. Our findings suggest that upregulation of 
S1P1 on tumor antigen-specific Treg mediates their prefer-
ential exit from the BM.
Materials and methods
Patient samples
Collection of PB and BM samples from cancer patients 
and healthy donors was performed in compliance with the 
norms of the ethics committee [“HLA compatible allo-
geneic cell therapy of human tumors in mouse model’’ 
(approval reference number 70/99)] of the University of 
Heidelberg upon signed consent. Samples were withdrawn 
from patients (29–73-year-old Caucasians) who did not 
receive neo adjuvant chemotherapy and healthy donors 
without a history of breast cancer (21–63  years old Cau-
casians) after informed consent. Age range of patients 
and healthy donors was matched. Formalin-fixed paraf-
fin-embedded (FFPE) tissue sections and cryosections of 
mammary tumors were provided by the tissue bank of the 
National Center for Tumor Diseases (NCT, Heidelberg, 
Germany) in accordance with the regulations of the tissue 
bank and the approval of the ethics committee of the Uni-
versity of Heidelberg.
Cell isolation
PB mononuclear cells (PBMCs) and BM mononuclear 
cells (BMMCs) were isolated using established protocols 
by Ficoll (Biocoll) gradient centrifugation. Cells from 
the interface were collected, washed twice with X-vivo 
20 medium (Lonza), and used directly for phenotyping 
using flow cytometry or purified and taken into culture for 
in vitro assays.
Cell purification
HLADR+ primary APC were isolated using HLA-DR 
Microbeads Human (Miltenyi Biotec, 130-046-101) as per 
the manufacturer’s instructions. Alternatively, DC were 
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differentiated in  vitro as per standard protocols described 
earlier [24]. CD4+ Tcon and Treg were isolated using 
Human CD4+ CD25+ Regulatory T-cell isolation kit 
(Miltenyi Biotec, 130-091-301) according to the manufac-
turer’s instructions.
Antibodies and flow cytometry
Tcon and Treg were phenotyped by flow cytometry 
(FACS Canto, BD Biosciences). Live cells were distin-
guished using Live/Dead Fixable Yellow Dead Cell Stain 
(Life Technologies, L34959) for 15  min at 4 °C followed 
by blocking with Kiovig (human plasma derived immu-
noglobulin, Baxter, PZN-4668835) at a concentration of 
100 µg/ml in PBS for 15 min at room temperature. Mono-
clonal anti-human S1P1-APC (R&D systems, FAB2016A) 
and corresponding mouse IgG2B isotype control (R&D 
systems, IC0041A) were used at concentrations recom-
mended by the manufacturer in PBS for 30 min at 37 °C. 
This was followed by surface staining for CD3-Alexa Fluor 
700 (Invitrogen, CD0329), CD4-Brilliant violet 421 (BD 
Biosciences, 562424) and CD25-PerCp Efluor 710 (eBio-
science, 46-0257-42) in PBS for 20 min at 4 °C. For some 
experiments, CD127-PECy7 (Biolegend, 351320) was used 
in conjunction to distinguish the CD127− Treg subsets. 
Cells were fixed and permeabilized using the fixation and 
permeabilization concentrate (eBioscience, 00-5123-43) 
and diluent (eBioscience, 00-5223-56) for 20  min at 4 °C 
followed by intracellular staining for FoxP3-FITC (Bioleg-
end, 320106) in 1× permeabilization solution (eBioscience, 
00-8333-56) for 20 min at 4 °C.
To detect antigen-specific T cells, DRB1*04:01 and 
DRB1*07:01 tetramers (PE conjugated) presenting mam-
maglobin as well as a negative control tetramer presenting 
a Class II-associated invariant chain (CLIP) peptide were 
obtained from NIH tetramer core facility (Emory Univer-
sity, Atlanta). Cells blocked with Kiovig were stained with 
tetramers (1 µg/100 µl PBS) for 1 h at 37 °C followed by 
staining with other antibodies as described above. HLA 
typing for the DRB1 locus was initially performed by 
FACS using mouse monoclonal HLADR-04 (Abcam, 
ab33903) or HLADR-07 (Abcam, ab34054-50) antibody 
for 15  min at 4 °C and detected using secondary rat anti-
mouse IgM-APC (BD Pharmingen, 50676) and later recon-
firmed by PCR. Data were collected using FACS Canto 
(BD Biosciences) with the FACS Diva software. Data anal-
ysis was done with FlowJo 8.8.6. Total number of events 
collected per sample varies between 0.05 mill and 0.8 mill 
cells. For all individual patients, Treg subsets were gated 
according to isotype control stainings (as shown in sup-
plementary Fig.  1). CD25+ FoxP3+ Treg were the core 
population of Treg that were analyzed. In addition, CD25+ 
subset, CD25+ CD127− subset, and CD25+ FoxP3+ 
CD127− subset were also analyzed. GraphPad Prism 6 was 
used for graphical representations and associated statistics.
ELISA
Plasma from PB and BM of patients were collected by cen-
trifugation at 3000 rpm for 5 min at room temperature. The 
clear supernatant was used for quantifying S1P concen-
trations using S1P ELISA kit (Echelon Boiosciences Inc, 
K-1900) as per the manufacturer’s instructions.
In vitro T‑cell activation assays
T-cell activation assays were performed by coculture of 
purified Treg as described above with either MACS puri-
fied fresh HLADR+ primary BM APC or by differentiat-
ing DC in vitro with the standard protocols using GMCSF 
(560 units/ml) and IL4 (500 units/ml) for 7 days. Treg were 
maintained in X-vivo medium with 300  units/ml IL2 (for 
Tcon 100 units/ml IL2 was used) and 60 units/ml IL4. BM 
APC were cocultured with Treg in the ratio 1:10 along with 
polyclonal stimulation using the Staphylococcus aureus 
enterotoxin B (SEB) (1  µg/ml) or cocultured with APC 
alone or left unstimulated. On day 3, cells were analyzed by 
flow cytometry.
Migration assay
MACS purified primary APC were cocultured with Treg/
Tcon in the ratio 1:10 along with polyclonal stimulation 
using SEB (1 µg/ml). Unstimulated cells were used as con-
trol. On day 3 after activation, calcein staining and migra-
tion assay were performed as described by Frevert et  al. 
[25]. Cells and chemoattractants were prepared in RPMI 
with 20 mM HEPES. 96 well-disposable chemotaxis plates 
(Neuroprobe) were coated with 10  µl of collagen (10  µg/
ml in 10 mM acetic acid). Chemoattractants were added to 
the lower chamber, and 50,000 calcein labeled Treg were 
added to the upper chamber. After incubation for 1  h at 
37 °C, cells that migrated to the lower well were read using 
a calcein reader (Perkin Elmer 2030 multi-label reader). 
Results obtained as fluorescence intensity units were nor-
malized to cells that migrated to medium alone.
Epigenetic Treg assay
Tumor areas on FFPE breast tumor sections were demar-
cated by Hematoxylin Eosin (H&E) stained reference 
slides and subsequently scraped into eppendorf tubes 
manually. DNA isolation and epigenetic quantification of 
Treg based on amplifying the Treg Specific Demethylated 
Region (TSDR) by qPCR were performed at Epiontis, 
Berlin as previously described [26]. Total Treg and CD3 
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T-cell numbers that infiltrated the tumor were quantified 
based on the number of GAPDH plasmid units obtained 
in each assay. Cell numbers were normalized to 1  mm3 
tumor volume.
Multicolour immunofluorescence staining and data 
acquisition using TissueFAXS
Intratumoral T-cell subpopulations were detected by 
a combination of primary antibodies: anti-CD3 (Dako, 
A0452, Host-rabbit), anti-CD8 (Clone YTC182.20, 
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Abcam, Ab60076, Host-rat), and anti-FOXP3 (Clone 
236  A/E7, Abcam, Ab20034, Host-mouse) on acetone-
fixed breast tumor cryosections as described earlier [27]. 
Primary specific secondary antibodies (anti-rabbit Alex-
afluor 647, A21245; anti-rat Alexa Fluor 488, A11006; 
anti-mouse Alexa Fluor 555, A31570) were purchased 
from Life Technologies. DAPI (Invitrogen, D1306) was 
utilized to stain cell nuclei.
Total tissue slides were scanned on Olympus IX51 
microscope equipped with a F-View II camera (both 
Olympus) and analyzed by the TissueQuest Cell Analy-
sis Software package (version 4.0.1.0137, TissueGnos-
tics GmbH). For automated analysis with TissueQuest, 
DAPI staining was used as a master marker for cell iden-
tification on the basis of nuclei detection. Based on H&E 
stained reference slides, regions of interest (ROI) were 
defined to distinguish between tumor and surrounding 
non-tumor area. All tissues were analyzed with identi-
cal parameters for detection of T cells based on nuclear 
size, mean staining intensity, and background threshold. 
Cells were visualized in scattergrams, while the cutoff 
between positive and negative gated cells was validated 
manually by backward gating on the original image.
Statistical analyses
Distributions of data were described by mean with the 
standard error of the mean (SEM) or median with inter-
quartile range as appropriate considering the form of the 
distribution. Consequently, the unpaired or paired t test 
or, respectively, the Wilcoxon matched pairs signed rank 
test were used to compare two different distributions test. 
Non-parametric Spearman Correlation was used to analyze 
the association between the frequency of Treg in BM and 
tumor. Two-way analysis of ANOVA with repeated meas-
urements in both factors (concentration and stimulation sta-
tus) and paired t tests as post hoc test was used for analyz-
ing migration potential of Treg to S1P. *p value <0.05; **p 
value <0.01; ***p value <0.001; ****p value <0.0001; 
Differences were considered statistically significant when 
p < 0.05.
Results
Treg in breast cancer patients are inversely distributed 
between BM and tumor tissue
We first compared Treg frequencies by flow cytometry in 
PB and BM of healthy individuals (PB n = 7 and BM n = 8) 
and 50 breast cancer patients using CD25, FoxP3, and CD4 
as Treg markers (Fig. 1a–c). Healthy individuals contained 
average Treg frequencies of 4.6% in PB, which is in accord-
ance with published literature [28] and slightly, but not 
significantly higher Treg frequencies in BM (mean: 5.7%) 
(Fig. 1d). In breast cancer patients, we observed in accord-
ance with published literature significantly increased fre-
quencies of Treg in PB (mean: 6.4%) which were elevated 
in 82% of the cases over mean values of the healthy donor 
control group. Strikingly, despite their increased Treg num-
bers in the blood, most of the patients harboured strongly 
reduced Treg frequencies in the BM (mean: 2.8%), result-
ing in a strong change of Treg distribution between both 
compartments from a BM: PB ratio of 1.2 (healthy donors) 
to 0.4 (patients). We likewise observed lower frequen-
cies of CD25+ among all CD4 T cells—(Supplementary 
Fig.  1a, g, h); and among all CD3 T cells—(Supplemen-
tary Fig.  2a–c) in the BM with a corresponding increase 
in the PB. Since in humans, FoxP3 can also be expressed 
by subsets of activated T cells, we did an additional assess-
ment of CD127 which is expressed by Tcon but not by Treg 
[29, 30]. Among CD4 T cells, we also observed reduced 
frequencies of CD25+ FoxP3+ CD127− (Supplementary 
Fig. 1b–d) and CD25+ CD127− (Supplementary Fig. 1e, f) 
Treg in BM as compared to PB. Thus, compared to healthy 
donors, breast cancer patients harbor reduced frequencies 
of Treg in their bone marrow despite an overall increased 
Fig. 1  Decreased frequencies of Treg subpopulations in the BM of 
breast cancer patients. a Representative plot of a healthy donor show-
ing the CD4+ T-cell gating strategy. b–c CD4+ cells were analyzed 
for FoxP3 and CD25 expression. CD25+ FoxP3+ cells were gated as 
Treg, and CD25− FoxP3− cells were gated as Tcon. Representative 
plots illustrating Treg frequencies in BM and PB of a healthy donor 
(b) and a breast cancer patient (c). Red circle and square represents 
the CD4 gate and CD25+ FoxP3+ Treg gate, respectively. d Cumu-
lative data of CD25+ FoxP3+ Treg frequencies in PB and BM of 
all patients and healthy donors analyzed—Healthy donor PB (n = 7) 
and BM (n = 8), patients with matched PB and BM samples (n = 50). 
Data distribution in 1d is represented by mean with SEM. For healthy 
donors unpaired t test and for patient samples, paired t test was used 
for statistical analysis. Epigenetic PCR was performed on DNA iso-
lated from tumor areas from FFPE sections obtained from 42 patients. 
Samples that passed quality control [Treg (n = 33) and CD3 (n = 40)] 
were taken into analysis. e, f Treg and CD3 T-cell percentage (e) and 
counts per  mm3 volume of tumor (f). Data distribution is represented 
by median with interquartile range in e and f. g Graph bridging data 
of Treg frequencies in BM, PB, and tumor—ratio of Treg in BM to 
PB correlated to ratio of Treg in tumor to PB [for all patients with 
Treg frequencies >4.6% in PB (n = 18)]. Non-parametric Spearman 
Correlation was used for analysis (Spearman r = −0.5170). Axes are 
depicted on log 2 scale. h. Graph depicting Treg counts in tumor and 
non-tumor areas of breast tissue (n = 7). Lines connect data from indi-
vidual patients. Non-parametric Wilcoxon matched pair signed rank 
test was used for statistical analysis. i Representative immunofluores-
cence staining of mammary tumor cryosection with arrows indicat-
ing CD4+ Treg and analyzed by the TissueQuest software. Cells that 
were DAPI+ FoxP3+ CD3+ and CD8− were defined as CD4+ Treg. 
Original magnification, 20×; Scale bar 20 µm
◂
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population of Treg in the blood. This raises the question, 
whether in breast cancer patients—in contrast to healthy 
donors—Treg populations might be mobilized from the 
bone marrow, e.g., followed by their immigration into 
tumor tissue.
Treg can rapidly migrate from the PB to tumors [3, 31]. 
To assess whether the loss of Treg from the BM was asso-
ciated with Treg accumulation in breast tumor tissue, we 
quantified by Epigenetic PCR Treg and CD3 T-cell infiltra-
tion in breast tumor samples of 42 patients. As shown in 
Fig.  1e and f, we detected a median infiltration of 3.56% 
Treg and 19.2% CD3 T cells among total tumor infiltrating 
cells resembling a calculated absolute number of 2951 Treg 
and 12,956 CD3+ T cells per  mm3.
We could correlate tumor infiltrating Treg in some of 
these tumor samples to the frequencies of Treg in the PB 
and BM of the same patients. We focused on those patients 
who showed elevated Treg frequencies in their PB over 
mean values in healthy individuals (4.6%) (Fig. 1d), as in 
these patients, a Treg response is likely. To normalize for 
the overall strong inter-individual heterogeneity in abso-
lute Treg levels among these patients, we determined for 
each patient the relative distribution of Treg between the 
BM and the tumor tissue by calculating the ratios with the 
respective Treg frequencies in the PB. We detected that 
reduced Treg frequencies in the BM significantly correlated 
with increased Treg infiltration in the corresponding breast 
tumors (Fig. 1g-i), suggesting that in breast cancer patients, 
Treg populations might shift from one to the other com-
partment. Such Treg accumulation in tumors appears to be 
tumor tissue selective as we detected by microscopic analy-
sis only little Treg infiltration in normal breast tissue of the 
same patients (Fig. 1h).
Tumor antigen‑specific Treg in the BM express high 
levels of S1P1
One major trigger of T-cell emigration from lymphoid 
organs is antigen-specific stimulation [15, 32]. We thus 
reasoned that the population of tumor antigen-specific 
Treg would be under-represented among BM-resident 
Treg in case T-cell receptor stimulation also triggered the 
observed selective reduction of Treg in the BM. To detect 
and phenotype breast tumor specific CD4+ Treg and Tcon 
cells by flow cytometry, we had previously developed 
MHC II tetramers (HLADR 04:01 and HLADR 07:01) 
loaded with MHC-allele restricted peptides derived from 
the breast tumor associated antigen mammaglobin I [13]. 
With these MHC II tetramers, we successfully detected 
increased frequencies of tumor specific Treg in the blood 
of breast cancer patients, while the occurrence of tumor 
antigen-specific Treg in healthy individuals’ blood is rare 
(0.07%) [13]. In accordance with our previous findings, 
we detected populations of tumor antigen-specific Treg in 
the PB of breast cancer patients. We also detected tumor 
specific Treg in their BM, but at significantly lower fre-
quencies than in the PB (Fig. 2a, b). Thus, tumor specific 
Treg were reduced among BM-resident Treg populations, 
suggesting that the loss of Treg from the BM of breast 
cancer patients involves, at least partially, TCR-mediated 
signals. To understand a possible mechanism that could 
mediate the mobilization of Treg from BM, we studied 
the expression of S1P1 on Treg (S1P1 antibody staining 
was tested on HTC Rat hepatoma cell line over express-
ing human S1P1 prior to staining on antigen-specific Treg 
in BM and PB—Supplementary Fig. 3). Interestingly, we 
observed a high expression of S1P1 only on tumor anti-
gen-specific Treg in the BM, while S1P1 expression was 
low on CD25+ FoxP3+ Treg, CD25-FoxP3-Tcon, tumor 
specific Tcon in PB and BM, and tumor specific Treg 
in PB (Fig. 2c, d). Thus, in breast cancer patients, S1P1 
expression characterizes a population of BM-resident 
tumor antigen-specific Treg, suggesting that S1P1 expres-
sion is related to TCR stimulation of Treg in the BM.
TCR stimulation induces S1P1 expression on BM Treg
As S1P1 was selectively upregulated on antigen-specific 
Treg in the BM, we studied the impact of TCR stimula-
tion on S1P1 expression. To this end, we purified Treg 
from the BM and polyclonally stimulated their TCRs 
using anti-CD3 and anti-CD28-coated beads (Fig.  3a). 
We also assessed the impact of antigen-presenting cell 
populations in the BM during polyclonal TCR stimula-
tion using SEB for cross-linking the TCRs to HLA-DR 
molecules [33] presented by either purified BM-derived 
autologous HLA-DR+ primary APC (Fig. 3b) or in vitro 
generated BM-derived dendritic cells (BMDC) (Fig. 3c). 
We assessed S1P1 expression 3 days after the respective 
stimulation procedure as Pham et al. reported that stimu-
lated murine effector T cells expressed the highest lev-
els of S1P1 after 3 days of activation [16]. As shown in 
Fig.  3a–d, TCR stimulation using anti-CD3 anti-CD28-
coated beads alone or coculture with either BM-derived 
primary APC or in vitro differentiated BMDC alone did 
not induce S1P1 expression on Treg. However, TCR 
stimulation by BM-derived APC populations that pre-
sented the bacterial superantigen SEB resulted in strong 
S1P1 expression. These results demonstrate that on the 
one hand side, antigen-specific stimulation through the 
TCR is crucial for upregulating S1P1 expression on Treg 
and on the other hand that the presence of APC together 
with TCR stimulation is necessary for S1P1 upregulation 
on Treg.
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Activated Treg migrate to S1P in vitro
We next assessed the concentrations of the ligand S1P in 
the BM and PB [34] of healthy donors and breast cancer 
patients. PB plasma S1P levels were significantly elevated 
in breast cancer patients compared to healthy donors. In 
contrast, S1P concentration in BM was lower than in PB of 
patients but similar to S1P concentrations present in BM of 
healthy individuals. Nevertheless, the highly elevated S1P 
concentration in patients’ PB resulted in a pronounced S1P 
concentration difference between the BM and the PB in 
breast cancer patients of 400 nM (Fig. 4a). We, therefore, 
assessed whether BM-derived Treg could migrate towards 
S1P concentrations similar to physiological levels of S1P 
Fig. 2  Mammaglobin specific Treg in BM expresses S1P1. a Dot 
plot depicting frequencies of mammaglobin specific Treg in PB and 
BM of a breast cancer patient. b Cumulative data of mammaglobin 
specific Treg frequencies in PB and BM of breast cancer patients 
(n = 10). c Graph showing MFI of S1P1 expression on bulk and 
antigen-specific Tcon and Treg in PB and BM and d Graph showing 
percentage of S1P1 positive BM Tcon and Treg from all DR04 and 
DR07 patients analyzed (n = 5). Data distribution is represented by 
mean with SEM in b–d. Paired t test was used for statistical analysis 
in b–d. Lines connect data from individual patients
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present in breast cancer patients. To this end, we purified 
Treg and Tcon from the BM of breast cancer patients and 
tested their migration towards different S1P concentrations. 
To assess a potential impact of TCR stimulation on the 
migration towards S1P, we subjected aliquots of the T cells 
to polyclonal TCR stimulation by coculturing them with 
purified autologous primary APC from the BM which were 
loaded with SEB.
We observed enhanced migration to increasing con-
centrations of S1P only in TCR stimulated Treg (Fig. 4b). 
Fig. 3  Antigen-specific TCR stimulation induces S1P1 expression on 
BM Treg. a Histogram of S1P1 expression on a patient’s BM Treg 
stimulated with anti-CD3 anti-CD28 beads (n = 3). b Histogram 
depicting S1P1 expression on a patient’s BM Treg stimulated with 
purified primary APC alone (n = 2) or primary APC with SEB (n = 5). 
c Histogram depicting S1P1 expression on a patient’s BM Treg stim-
ulated with in vitro differentiated BMDC alone or BMDC with SEB 
(n = 4) three days after activation. Red line in the histograms depict 
S1P1 expression on unstimulated Treg alone. Green line in the his-
tograms refer to S1P1 expression on TCR stimulated Treg. Blue line 
(only in b and c) refers to S1P1 expression on Treg that were cocul-
tured with APC or BMDC alone without the polyclonal SEB stimu-
lus. Solid grey histogram represents S1P1 isotype control. d Cumu-
lative data from three different stimulation settings. Paired t test was 
used (when n is > or =4) for statistical analysis
Fig. 4  In vitro activated BM Treg migrate to S1P. a Quantifica-
tion of S1P concentrations in PB and BM (n = 12) plasma of healthy 
donors and breast cancer patients (n = 39) by ELISA. For healthy 
donors unpaired t test and for patient samples, paired t test was used 
for statistical analysis. b–c Migration index (flourescence intensity 
units of cells that migrated to chemoattractant/flourescence intensity 
units of cells that migrated to medium alone) of BM Treg (b) and 
Tcon (c) towards S1P (n = 4). d–e Migration index of Treg (d) and 
Tcon (e) towards CXCL12 as control (n = 2). Distribution of data is 
represented by mean with SEM. Two-way analysis of ANOVA with 
repeated measurements was performed with concentration as one fac-
tor and stimulation status as the other factor. Concentration (p value 
0.0010), stimulation (p value 0.0494), and interaction between con-
centration and stimulation (p value 0.0155) suggesting a different 
influence of stimulation depending on the concentration. Post hoc 
paired t tests showed a significant influence of stimulation in the two 
highest concentrations (1000 and 10,000 nM S1P)
Cancer Immunol Immunother 
1 3
In contrast, Tcon did not migrate to S1P irrespective of 
their activation status (Fig.  4c). Unstimulated as well as 
stimulated Treg migrated well towards CXCL12 used as 
a positive control in the migration assays confirming that 
unstimulated Treg were generally capable of responding to 
chemotactic stimuli (Fig. 4d). Tcon migrated to CXCL12 in 
unstimulated conditions but upon activation, the migration 
to CXCL12 was very much reduced (Fig. 4e). This was a 
reflection of the downregulation of the CXCL12 receptor 
CXCR4 upon activation (data not shown). Cumulatively, 
these results demonstrate that activated BM Treg inherently 
sense and migrate towards S1P.
Discussion
While increased infiltration of Treg into solid tumors has 
often been described, factors driving their migration from 
lymphoid organs into cancerous tissues largely remain 
elusive. Previous work published by Peters et al. [35] sug-
gested that Treg trafficking patterns might be strongly per-
turbed in solid tumor patients. A potential role of the BM 
for Treg recirculation in cancer patients has been already 
suggested by Zhao et al. [36]. Here, we show for the first 
time in breast cancer patients, major changes in Treg dis-
tribution between BM, PB, and tumor. This was character-
ized by an overall increase in PB, markedly decreased Treg 
frequencies in BM and an associated Treg accumulation in 
tumor tissue, suggesting that Treg might be mobilized from 
the BM into the blood and tumor. Because of high varia-
tions in overall Treg abundance between the breast cancer 
patients which might reflect different dynamics in Treg 
generation and because of potentially very short recircula-
tion periods of activated, mobilized Treg in the blood, we 
could not directly identify an inverse correlation between 
their frequencies in the blood and bone marrow. However, 
we could show that in breast cancer patients, Treg distri-
bution is inversely correlated between bone marrow and 
tumor tissue.
An exploratory assessment of CD25+ FoxP3+ Treg in 
50 patients revealed that this characteristic Treg distribu-
tion pattern was observed in patients with different grades 
(Grades I, II, and III) with no significant differences with 
varying disease grades (data not shown). Interestingly, 
tumor antigen-specific Treg were significantly under-rep-
resented in the BM compared to the blood—pointing to 
the possibility of a link between TCR stimulation and Treg 
depletion in the BM. This was corroborated by our finding 
of selective S1P1 expression on tumor antigen-specific BM 
Treg. However, our in vitro activation experiments showed 
that TCR stimulation by CD3 CD28-coated beads alone did 
not induce S1P1 expression in Treg but that S1P1 surface 
expression on Treg required additional signals provided 
by APC emphasizing their importance in regulating S1P1 
expression. In this regard, Shannon et al. have attributed a 
role for CCL19 in inducing S1P1 expression on murine T 
lymphocytes [37]. As CCL19 can be secreted by APC sub-
sets [38], it would be interesting to unravel the nature of 
putative CCL19+ BM APC that could potentially present 
breast tumor antigens to Treg.
Since extracellular S1P is required for signaling via 
S1P1 on the cell surface, the exploitation of such S1P1 
mediated mobilization of antigen specific Treg seems to be 
based on two conditions; first -a Treg selective induction of 
S1P1 through the presentation of cognate antigen by APC 
in the BM, and second—increased concentrations of S1P 
in PB plasma that have been previously reported in patients 
with solid tumors [39]. Here, we show that in breast cancer 
patients, BM S1P levels are not elevated despite increased 
PB plasma S1P levels creating an S1P gradient between the 
BM and PB. Multiple cell types that can secrete S1P [40] 
and produce sphingosine kinases that regulate the phospho-
rylation and release of S1P [41] have been described and 
might contribute to the observed S1P gradient between BM 
and PB in cancer patients.
A putative role for S1P1 in regulating Treg traffick-
ing from human BM to PB has not been studied so far, 
although S1P1 surface expression has been reported on 
human CD4+ T cells subjected to serum starvation [42]. 
In our in vitro migration experiments, only TCR stimulated 
Treg migrated to S1P, whereas resting Treg did not. This 
result is in accordance with the work of Ishimaru et al. who 
previously reported that murine lymph node Treg activated 
with anti CD3 antibody migrated to S1P [22], thus empha-
sizing the importance of Treg activation to respond to S1P 
signals.
Our finding that S1P1 was scarcely expressed by tumor 
antigen-specific Tcon but strongly and specifically induced 
in tumor antigen-specific Treg hints towards a role for BM 
APC in the regulation and maintenance of peripheral tol-
erance—e.g., through mobilizing populations of self reac-
tive Treg for dampening chronic inflammatory processes 
at peripheral sites. The reduced migratory potential of 
activated Tcon to S1P could be explained by work of Liu 
et  al. who demonstrated that after TCR stimulation, Treg 
maintain S1P1 surface expression, while Tcon rapidly 
loose S1P1 expression [23]. Taken together, our study sug-
gests that BM may be an important site for the activation 
of tumor antigen-specific Treg that get preferentially mobi-
lized from the BM into PB via S1P1. Increased PB plasma 
S1P levels as well as the capacity of APC to induce S1P1 
expression on Treg through TCR stimulation may con-
tribute to such peripheral tolerance mechanism. In cancer 
patients, this preferential mobilization of antigen-specific 
Treg mediated by S1P1 from the BM might act as a pre-
ceding step in the Treg trafficking process resulting in their 
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accumulation in tumor thus contributing to poor clinical 
responses. Therefore, disrupting increased S1P levels pre-
vailing in PB plasma of cancer patients may represent a 
future therapeutic strategy to contain Treg within the BM 
thereby reducing Treg infiltration into tumors.
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